Sichuan Biokin Pharmaceutical Files for Hong Kong IPO: Yizekang Becomes World's First Approved Bispecific ADC with 15 Clinical-Stage Pipeline Candidates

NewTimeSpace News: Sichuan Biokin Pharmaceutical Co., Ltd. filed its listing application with the Hong Kong Stock Exchange on 6 August, with CITIC Securities, Jefferies, CICC and Deutsche Bank acting as joint sponsors. The Company previously advanced its listing process on 12 November 2025 before deferring, and has now refiled.

Founded in 1996, the Company is an integrated biopharmaceutical group dedicated to advancing breakthrough innovation, developing oncology therapies with breakthrough efficacy and bringing them to patients worldwide. In 2014, the Company established SystImmune, Inc. in Seattle to build its presence in the global biotechnology innovation industry and lead 0-to-1 breakthrough innovation, leveraging its domestic R&D, translational medicine and clinical development systems as capability supplements to accelerate the 1-to-N clinical translation and indication expansion of its self-developed pipeline assets.

In respect of its R&D pipeline, as of the latest practicable date, the Company's innovative drug pipeline comprises 15 clinical-stage drug candidates, five of which are undergoing clinical development outside China. The Company focuses on oncology and has strategically positioned itself in three frontier technology tracks: antibody-drug conjugates (ADC), antibody-radionuclide conjugates (ARC) and multispecific T-cell engagers (TCE).

The Company owns two core products, Yizekang and T-Bren. Yizekang has pioneered the entirely new field of bispecific ADC drugs, being the world's first and only bispecific antibody ADC approved for marketing to date, and the only EGFR×HER3 bispecific ADC to have entered the global registration stage. Its New Drug Applications (NDA) for later-line treatment of nasopharyngeal carcinoma (NPC) and second-line treatment of esophageal squamous cell carcinoma (ESCC) were approved by China's NMPA in June 2026 and July 2026 respectively, and its NDA for the treatment of triple-negative breast cancer (TNBC) has also been accepted by the NMPA. T-Bren, on the other hand, is a human epidermal growth factor receptor 2 (HER2) ADC with best-in-class potential, currently undergoing registrational clinical development for multiple HER2-expressing solid tumors.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.